Translating the evidence for gene association with depression into mouse models of depression-relevant behaviour: Current limitations and future potential

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 8, 2013, Pages 1380-1402

  Pryce, Christopher R ^a,b   Klaus, Federica ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Aetio pathology; Depression; Expression; Gene polymorphism; Gene environment; Mouse model; Psychopathology; Stress

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID 2 RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR 4; DOPAMINE TRANSPORTER; FK 506 BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT 3; NEUROPEPTIDE Y; NORADRENALIN; OPIATE PEPTIDE; SEROTONIN TRANSPORTER; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APOE GENE; BDNF GENE; C5ORF20 GENE; CHROMOSOME 5; CRHR1 GENE; DEPRESSION; DNA POLYMORPHISM; DRD4 GENE; ELECTROENCEPHALOGRAM; ENDOPHENOTYPE; ENVIRONMENTAL FACTOR; FKBP5 GENE; FUTUROLOGY; GENE; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC COMPLEMENTATION; GENETIC REGULATION; GENETICS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; GNB3 GENE; HETEROZYGOTE; HUMAN; MTHFR GENE; NONHUMAN; NPY GENE; OPCMI GENE; OPCML GENE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A2 GENE; SLC6A3 GENE; SLC6A4 GENE; STRESS; TNF GENE;

AETIO-PATHOLOGY; DEPRESSION; EXPRESSION; GENE POLYMORPHISM; GENE-ENVIRONMENT; MOUSE MODEL; PSYCHOPATHOLOGY; STRESS;

ANIMALS; BEHAVIOR, ANIMAL; DEPRESSION; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; POLYMORPHISM, GENETIC;

EID: 84879726822     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.05.003     Document Type: Review

References (162)

1. Aan Het Rot M., Zarate C.A., Charney D.S., Mathew S.J. Ketamine for depression: where do we go from here?. Biol. Psychiatry 2012, 72:537-547.
2. Adamec R., Burton P., Blundell J., Murphy D.L., Holmes A. Vulnerability to mild predator stress in serotonin transporter knockout mice. Behav. Brain Res. 2006, 170:126-140.
3. Alexander N., Klucken T., Koppe G., Osinsky R., Walter B., Vaitl D., Sammer G., Stark R., Hennig J. Interaction of the serotonin transporter-linked polymorphic region and environmental adversity: increased amygdala-hypothalamus connectivity as a potential mechanisms linking neural and endocrine hyperreactivity. Biol. Psychiatry 2012, 72:49-56.
4. Alexander N., Kuepper Y., Schmitz A., Osinsky R., Kozyra E., Hennig J. Gene-environment interactions predict cortisol responses after acute stress: implcations for the etiology of depression. Psychoneuroendocrinology 2009, 34:1294-1303.
5. Ansorge M.S., Hen R., Gingrich J.A. Neurodevelopmental origins of depressive disorders. Curr. Opin. Pharmacol. 2007, 7:8-17.
6. APA Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC, (Revision). 4th edn.
7. Aston C., Jiang L., Sokolov B.P. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol. Psychiatry 2005, 10:309-322.
8. Bale T.L., Vale W.W. Increased depression-like behaviors in corticotropin-releasing factor receptor-2 deficient mice: sexually dichotomous responses. J. Neurosci. 2003, 23:5295-5301.
9. Benito C., Tolon R.M., Pazos M.R., Nunez E., Castillo A.I., Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol. 2008, 153:277-285.
10. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
11. Bezard E., Dovero S., Belin D., Duconger S., Jackson-Lewis V., Przedborski S., Piazza P.V., Gross C.E., Jaber M. Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J. Neurosci. 2003, 23:999-1007.
12. Bosker F.J., Hartman C.A., Nolte I.M., Prins B.P., Terpstra P., Posthuma D., van Veen T., Willemsen G., DeRijk R.H., de Geus E.J., Hoogendijk W.J., Sullivan P.F., Penninx B.W., Boomsma D.I., Snieder H., Nolen W.A. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol. Psychiatry 2011, 16:516-532.
13. Bradley R.G., Binder E.B., Epstein M.P., Tang Y., Nair H.P., Liu W., Gillespie C.F., Berg T., Evces M., Newport D.J., Stowe Z.N., Heim C.M., Nemeroff C.B., Schwartz A., Cubells J.F., Ressler K.J. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry 2008, 65:190-200.
14. Bröer A., Tietze N., Kowalczuk S., Chubb S., Munzinger M., Bak L.K., Bröer S. The orphan transporter v7-3 (slc6a15) is a Na+-dependent neutral amino acid transporter (B0AT2). Biochem. J. 2006, 393:421-430.
15. Bymaster F.P., Lee T.C., Knadler M.P., Detke M.J., Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharmaceut. Des. 2005, 11:1475-1493.
16. Cagniard B., Balsam P.D., Brunner D., Zhuang X. Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 2006, 31:1362-1370.
17. Carola V., Frazzetto G., Pascucci T., Audero E., Puglisi-Allegra S., Cabib S., Lesch K.-P., Gross C. Identifying molecular substrates in a mouse model of the serotonin transporter×environment risk factor for anxiety and depression. Biol. Psychiatry 2008, 63:840-846.
18. Carroll J.C., Boyce-Rustay J.M., Millstein R., Yang R.J., Wiedholz L.M., Murphy D.L., Holmes A. Effects of mild early life stress on abnormal emotion-related behaviors in 5-HTT knockout mice. Behav. Genet. 2007, 37:214-222.
19. Caspi A., Hariri A.R., Holmes A., Uher R., Moffitt T.E. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 2010, 167:509-527.
20. Caspi A., Moffitt T.E. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat. Rev. Neurosci. 2006, 7:583-590.
21. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Honalee H., McClay J., Mill J., Martin J.B., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
22. Causton H.C., Quackenbusch J., Brazma A. Microarray Gene Expression Data Analysis: a beginner's guide 2003, Blackwell Science, Oxford.
23. Chen Z.-Y., Jing D., Bath K.G., Ieraci A., Khan T., Siao C.-J., Herrera D.G., Toth M., Yang C., McEwen B.S., Hempstead B.L., Lee F.S. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006, 314:140-143.
24. Choudary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., Myers R.M., Bunney W.E., Akil H., Watson S.J., Jones E.G. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. PNAS 2005, 102:15653-15658.
25. Crawley J., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharm. Biochem. Behav. 1980, 13:167-170.
26. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005, 29:571-625.
27. Danese A., Caspi A., Williams B., Ambler A., Sugden K., Mika J., Werts H., Freeman J., Pariante C.M., Moffitt T.E., Arseneault L. Biological embedding of stress through inflammation processes in childhood. Mol. Psychiatry 2010, 16:244-246.
28. Danese A., Pariante C.M., Caspi A., Taylor A., Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. PNAS 2007, 104:1319-1324.
29. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-57.
30. Dawson G.R., Tricklebank M.D. Use of the elevated plus maze in the search for novel anxiolytic agents. TiPS 1995, 16:33-36.
31. de Bodinat C., Guardiola-Lemaitre B., Mocaer E., Renard P., Munoz C., Millan M.J. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat. Rev. Drug Discov. 2010, 9:628-642.
32. De Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005, 6:463-475.
33. Dell'Osso B., Palazzo M.C., Oldani L., Altamura A.C. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci. Ther. 2011, 17:723-732.
34. Disner S.G., Beevers C.G., Haigh E.A.P., Beck A.T. Neural mechanisms of the cognitive model of depression. Nat. Rev. Neurosci. 2011, 12:467-477.
35. Donovan D.M., Miner L.L., Perry M.P., Revay R.S., Sharpe L.G., Przedborski S., Kostic V., Philpot R.M., Kirstein C.L., Rothman R.B., Schindler C.W., Uhl G.R. Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Mol. Brain Res. 1999, 73:37-49.
36. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
37. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 2008, 213:93-118.
38. Duman R.S., Li N., Liu R.-J., Duric V., Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012, 62:35-41.
39. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
40. Duncan L.E., Keller M.C. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am. J. Psychiatry 2011, 168:1041-1049.
41. Fagiolini M., Jensen C.L., Champagne F.A. Epigenetic influences on brain development and plasticity. Curr. Opin. Neurobiol. 2009, 19:207-212.
42. Falzone T.L., Gelman D.M., Young J.I., Grandy D.K., Low M.J., Rubinstein M. Absence of dopamine D4 receptors results in enhanced reactivity to unconditioned, but not conditioned, fear. Eur. J. Neurosci. 2002, 15:158-164.
43. Fernandez-Ruiz J., Romero J., Velasco G., Tolon R.M., Ramos J.A., Guzman M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. TiPs 2006, 28:39-45.
44. Flake N.M., Zweifel L.S. Behavioral effects of pulp exposure in mice lacking cannabinoid receptor 2. J. Endodont. 2012, 38:86-90.
45. Gainetdinov R.R., Jones S.R., Fumagalli F., Wightman R.M., Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res. Rev. 1998, 26:148-153.
46. Gaysina D., Cohen S., Craddock N., Farmer A., Hoda F., Korszun A., Owen M.J., Craig I.W., McGuffin P. No association with the 5,10-methylenetetrahydrofolate reductase gene and major depressive disorder: results of the depression case control (DeCC) study and a meta-analysis. Am. J. Med. Genet. Part B 2008, 147B:699-706.
47. Giros B., Jaber M. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
48. Grabe H.-J., Schwahn C., Appel K., Mahler J., Schulz A., Spitzer C., Fenske K., Barnow S., Lucht M., Freyberger H.-J., John U., Teumer A., Wallaschofski H., Nauck M., Völzke H. Childhood maltreatment, the corticotropin-releasing hormone receptor gene and adult depression in the general population. Am. J. Med. Genet. Part B 2010, 153B:1483-1493.
49. Gray J.A., McNaughton N. The Neuropsychology of Anxiety: An Enquiry into the Functions of the Septo-hippocampal system 2000, Oxford University Press, Oxford. 2nd ed.
50. Haddley K., Vasiliou A.S., Ali F.R., Paredes U.M., Bubb V.J., Quinn J.P. Molecular genetics of monoamine transporters: relevance to brain disorders. Neurochem. Res. 2008, 33:652-667.
51. Haenisch B., Bilkei-Gorzo A., Caron M.G., Bönisch H. Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression. J. Neurochem. 2009, 111:403-406.
52. Haenisch B., Bönisch H. Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol. Ther. 2011, 129:352-368.
53. Haenisch B., Linsel K., Brüss M., Gilsbach R., Propping P., Nöthen M.M., Rietschel M., Fimmers R., Maier W., Zobel A., Höfels S., Guttenthaler V., Göthert M., Bönisch H. Association of major depression with rare functional variants in norepinephrine transporter and serotonin1A receptor genes. Am. J. Med. Genet. Part B (Neuropsych. Genet.) 2008, 150B:1013-1016.
54. Hall F.S., Drgonova J., Goeb M., Uhl G.R. Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacology 2003, 28:1485-1490.
55. Haller J., Bakos N., Rodriguiz R.M., Caron M.G., Wetsel W.C., Liposits Z. Behavioral responses to social stress in noradrenaline transporter knockout mice: effects on social behavior and depression. Brain Res. Bull. 2002, 58:279-284.
56. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002, 297:400-403.
57. Hasler G., Northoff G. Discovering imaging endophenotypes for major depression. Mol. Psychiatry 2011, 16:604-619.
58. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., Sjögren M., Asberg M., Ekman R., Wahlestedt C., Agren H. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J. Psychiat. Res. 2004, 38:113-121.
59. Helms C.M., Gubner N.R., Wilhelm C.J., Mitchell S.H., Grandy D.K. D4 receptor deficiency in mice has limited effects on impulsivity and novelty seeking. Pharm. Biochem. Behav. 2008, 90:387-393.
60. Holmes A., Li Q., Murphy D.L., Gold E., Crawley J.N. Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav. 2003, 2:365-380.
61. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
62. Ineichen C., Sigrist H., Spinelli S., Lesch K.-P., Sautter E., Seifritz E., Pryce C.R. Establishing a probabilistic reversal learning test in mice: evidence for the processes mediating reward-stay and punishment-shift behaviour and for their modulation by serotonin. Neuropharmacology 2012, 63:1012-1021.
63. Insel T., Cuthbert B., Garvey M., Heinssen R., Pine D.S., Quinn K., Sanislow C., Wang P. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 2010, 167:748-751.
64. Jackson I.J., Abbott C.M. Mouse Genetics and Transgenics: A Parictical Approach 2000, 247-284. Oxford University Press, Oxford.
65. Jadavji N., Deng L., Leclerc D., Malysheva O., Bedell B.J., Caudill M.A., Rozen R. Severe methylenetetrahydrofolate reductase deficiency in mice results in behavioral anomalies with morphological and biochemical changes in hippocampus. Mol. Genet. Metab. 2012, 106:149-159.
66. Jasinska A.J., Lowry C.A., Burmeister M. Serotonin transporter gene, stress and raphe-raphe interactions: a molecular mechanism of depression. Trends Neurosci. 2012, 35:395-402.
67. Jennings K.A., Lesch K.-P., Sharp T., Cragg S.J. Non-linear relationship between 5-HT transporter gene expression and frequency sensitivity of 5-HT signals. J. Neurochem. 2010, 115:965-973.
68. Jennings K.A., Loder M.K., Sheward W.J., Pei Q., Deacon R.M.J., Benson M.A., Olverman H.J., Hastie N.D., Harmar A.J., Shen S., Sharp T. Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J. Neurosci. 2006, 26:8955-8964.
69. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. PNAS 1998, 95:4029-4034.
70. Kang H.J., Adams D.H., Simen A., Simen B.B., Rajkowska G., Stockmeier C.A., Overholser J.C., Meltzer H.Y., Jurjus G.J., Konick L.C., Newton S.S., Duman R.S. Gene expression profiling in prefronal cortex of major depressive disorder. J. Neurosci. 2007, 28:13329-13340.
71. Karg K., Burmeister M., Shedden K., Den S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited. Arch. Gen. Psychiatry 2011, 68:444-454.
72. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R.S., Rodrigues A.L.S. Depressive-like behavior induced by tumor necrosis factor-a in mice. Neuropharmacology 2012, 62:419-426.
73. Kaufman J., Yang B.-Z., Douglas-Palumberi H., Grasso D., Lipschitz D., Houshyar S., Krystal J.H., Gelernter J. Brain-derived neurotrophic factor - 5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol. Psychiatry 2006, 59:673-680.
74. Kendler K.S., Hettema J.M., Butera F., Gardner C.O., Prescott C.A. Life event domensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety. Arch. Gen. Psychiatry 2003, 60:789-796.
75. Klempan T.A., Sequeira A., Canetti L., Lalovic A., Ernst C., ffrench-Mullen J., Turecki G. Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol. Psychiatry 2009, 14:175-189.
76. Koetsier G.C., Volkers A.C., Tulen J.H.M., Passchier J., van den Broek W.W., Bruijn J.A. CPT performance in major depressive disorder before and after treatment with imipramine or fluvoxamine. J. Psychiat. Res. 2002, 36:391-397.
77. Kohli M.A., Lucae S., Saemann P.G., Schmidt M.V., Demirkan A., Hek K., Czamara D., Alexander M., Salyakina D., Ripke S., Hoehn D., Specht M., Menke A., Hennings J., Heck A., Wolf C., Ising M., Schreiber S., Czisch M., Müller M.B., Uhr M., Bettecken T., Becker A., Schramm J., Rietschel M., Maier W., Bradley B., Ressler K.J., Nöthen M.M., Cichon S., Craig I.W., Breen G., Lewis C.M., Hofman A., Tiemeler H., van Duijn C.M., Holsboer F., Müller-Myhsok B., Binder E.B. The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron 2011, 70:252-265.
78. Krishnan V., Han M.-H., Graham D.L., Berton O., Renthal W., Russo S.J., LaPlant Q., Graham A., Lutter M., Lagace D.C., Ghose S., Reister R., Tannous P., Green T.A., Neve R.L., Chakravarty S., Kumar A., AJ E., Self D.W., Lee F.S., Tamminga C.A., Cooper D.C., Gershenfeld H.K., Nestler E.J. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007, 131:391-404.
79. Lesch K.-P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Müller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
80. Levav-Rabkin T., Blumkin E., Galron D., Golan H.M. Sex-dependent behavioral effects of Mthfr deficiency and neonatal GABA potentiation in mice. Behav. Brain Res. 2011, 216:505-513.
81. Line S.J., Barkus C., Coyle C., KJennings K.A., Deacon R.M.J., Lesch K.P., Sharp T., Bannerman D.M. Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur. Neuropsychopharmacol. 2011, 21:108-116.
82. Lopez-Leon S., Croes E.A., Sayed-Tabatabaei F.A., Claes S., Van Broeckhoven C., Van Duijn C.M. The dopamine D4 reecptor gene 48-base-pair-repeat polymorphism and mood disorders: a meta-analysis. Biol. Psychiatry 2005, 57:999-1003.
83. Lopez-Leon S., Janssens A.C.J.W., Gonsalez-Zuleoeta Ladd A.M., Del-Favero J., Claes S.J., Oostra B.A., van Duijn C.M. Meta-analyses of genetic studies on major depressive disorder. Mol. Psychiatry 2008, 13:772-785.
84. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
85. Lu A., Steiner M.A., Whittle N., Vogl A.M., Walser S.M., Ableitner M., Refojo D., Ekker M., Rubenstein J.L., Stalla G.K., Singewald N., Holsboer F., Wotjak C.T., Wurst W., Deussing J.M. Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol. Psychiatry 2008, 13:1028-1042.
86. Lucki I., Dalvi A., Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 2001, 155:315-322.
87. MacQueen G.M., Ramakrishnan K., Croll S.D., Siuciak J.A., Yu G., Young L.T., Fahnestock M. Performance of heterozygous brain-derived neurotropic factor knockout mice on behavioral analogues of anxiety, nociception, and depression. Behav. Neurosci. 2001, 115:1145-1153.
88. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genom. Hum. Genet. 2000, 1:507-537.
89. Manolio T.A. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 2010, 363:166-176.
90. Martinovich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat. Neurosci. 2007, 10:1089-1093.
91. Mathews T.A., Fedele D.E., Coppelli F.M., Avila A.M., Murphy D.L., Andrews A.M. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J. Neurosci. Methods 2004, 140:169-181.
92. Mayberg H.S. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br. Med. Bull. 2003, 65:193-207.
93. McGowan P.O., Sasaki A., D'Alessio A.C., Dymov S., Labonte B., Szyf M., Turecki G., Meaney M.J. Epigenetic regulation of the glucocorticoid receptor in human brain associates with child abuse. Nat. Neurosci. 2009, 12:342-348.
94. Mickey B.J., Zhou Z., Heitzeg M.H., Heinz E., Hodgkinson C.A., Hsu D.T., Langenecker S.A., Love T.M., Pecina M., Shafir T., Stohler C.S., Goldman D., Zubieta J.-K. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch. Gen. Psychiatry 2011, 68:158-166.
95. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
96. Miller R., Wankerl M., Stalder T., Kirschbaum C., Alexander N. The serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cortisol stress reactivity: a meta-analysis. Mol. Psychiatry 2012, 65:732-741.
97. Molina-Holgado F., Lledo A., Guaza C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 1997, 8:1929-1933.
98. Montanez S., Owens W.A., Gould G.G., Murphy D.L., Daws L.C. Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice. J. Neurochem. 2003, 86:210-219.
99. Murphy S.E., Norbury R., Godllewska B.R., Cowen P.J., Mannie Z.M., Harmer C.J., Munafo M.R. The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis. Mol. Psychiatry 2012, 18:512-520.
100. Murray E.A., Wise S.P., Drevets W.C. Localization of dysfunction in major depressive disorder: prefrontal cortex and amygdala. Biol. Psychiatry 2011, 69:e43-e54.
101. Nemeroff C.B. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol. Psychiatry 1996, 1:336-342.
102. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
103. Oak J.N., Oldenhof J., van Tol H.H.M. The dopamine D4 receptor: one decade of research. Eur. J. Pharmacol. 2000, 405:303-327.
104. Onaivi E.S., Ishiguro H., Gong J.-P., Patel S., Meozzi P.A., Myers L., Perchuk A., Mora Z., Tagliaferro P.A., Gardner E., Brusco A., Akinshola B.E., Liu Q.R., Chirwa S.S., Hope B., Lujilde J., Inada T., Iwasaki S., Macharia D., Teasenfitz L., Arinami T., Uhl G.R. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann. N. Y. Acad. Sci. 2008, 1139:434-449.
105. Onaivi E.S., Ishiguro H., Sejal P., Meozzi P.A., Myers L., Tagliaferro P.A., Hope B., Leonard C.M., Uhl G.R., Brusco A., Gardner E. Methods to study the behavioral effects and expression of CB2 cannabinoid receptors and its gene transcripts in chronic mild stress model of depression. Marijuana and Cannabinoid Research. Methods and Protocols Series: Methods in Molecular Medicine 2006, Vol. 123:291-298. Humana Press, New York.
106. Owens M., Goodyer I.M., Wilkinson P., Bhardwaj A., Abbott R., Croudace T., Dunn V., Jones P.B., Walsh N.D., Ban M., Sahakian B.J. 5-HTTLPR and early childhood adversities moderate cognitive and emotional processing in adolescence. PLoS One 2012, 7:e48482.
107. Painsipp E., Herzog H., Sperk G., Holzer P. Sex-dependent control of murine emotional-affective behavior in health and colitis by peptide YY and neuropeptide Y. Br. J. Pharmacol. 2011, 163:1302-1314.
108. Palin K., Bluthe R.-M., McCusker R.H., Levade T., Moos F., Dantzer R., Kelley K.W. The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFa-induced sickness behavior. Psychopharmacology (Berl) 2009, 201:549-556.
109. Parsey R.V., Hastings R.S., Oquendo M.A., Hu X., Goldman D., Huang Y.-y.Simpson N., Arcement J., Huang Y., Ogden R.T., Van Heertum R.L., Arango V., Mann J.J. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am. J. Psychiatry 2006, 163:48-51.
110. Patel A., Siegel A., Zalcman S.S. Lack of aggression and anxiolytic-like behavior in TNF receptor (TNF-R1 and TNF-R2) deficient mice. Brain Behav. Immunity 2010, 24:1276-1280.
111. Perona M.T.G., Waters S., Hall F.S., Sora I., Lesch K.-P., Murphy D.L., Caron M., Uhl G.R. Animal models of depression in dopamine, serotonin and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav. Pharmacol. 2008, 19:566-574.
112. Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature 2010, 465:721-727.
113. Pogorelov V.M., Rodriguiz R.M., Insco M.L., Caron M.G., Wetsel W.C. Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene. Neuropsychopharmacology 2005, 30:1818-1831.
114. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
115. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 2003, 463:3-33.
116. Pryce C.R., Azzinnari D., Sigrist H., Gschwind T., Lesch K.-P., Seifritz E. Establishing a learned helplessness effect paradigm in C57BL/6 mice: behavioural evidence for emotional, motivational and cognitive effects of aversive uncontrollability per se. Neuropharmacology 2012, 62:358-372.
117. Pryce C.R., Azzinnari D., Spinelli S., Seifritz E., Tegethoff M., Meinlschmidt G. Helplessness: a systematic translational review of theory and evidence for its relevance to understanding and treating depression. Pharmacol. Ther. 2011, 132:242-267.
118. Pryce C.R., Seifritz E. A translational research framework for enhanced validity of mouse models of psychopathological states in depression. Psychoneuroendocrinology 2011, 36:308-329.
119. Ressler K.J., Bradley B., Mercer K.B., Deveau T.C., Smith A.K., Gillespie C.F., Nemeroff C.B., Cubells J.F., Binder E.B. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. Am. J. Med. Genet. B Neuropsychiatric Genet. 2010, 153B:812-824.
120. Romero-Zerbo S.-Y., Garcia-Gutierrez M.S., Suarez J., Rivera P., Ruz-Maldonado I., Vida M., Rodriguez de Fonseca F., Manzanares J., Bermudez-Silva F.J. Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice. J. Neuroendocrinol. 2012, 24:1106-1119.
121. Rubenstein M., Phillips T.J., Bunzow J.R., Falzone T.L., Dziewczapolski G., Zhang G., Grandy D.K. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 1997, 90:991-1001.
122. Rudin M. Noninvasive structural, functional, and molecular imaging in drug development. Curr. Opin. Chem. Biol. 2009, 13:1-12.
123. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., Agerman K., Haapasalo A., Nawa H., Aloyz R., Ernfors P., Castren E. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 2003, 23:349-357.
124. Schiepers O.J.G., Wichers M.C., Maes M. Cytokines and major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2005, 29:201-217.
125. Schol-Gelok S., Janssens A.C.J.W., Tiemeier H., Liu F., Lopez-Leon S., Zorkoltseva I.V., Axenovich T.I., van Swieten J.C., Uitterlinden A.G., Hofman A., Aulchenko Y.S., Oostra B.A., van Duijn C.M. A genome-wide screen for depression in two independent Dutch populations. Biol. Psychiatry 2010, 68:187-196.
126. Schuhmacher A., Lennertz L., Wagner M., Höfels S., Pfeiffer U., Guttenthaler V., Maier W., Zobel A., Mössner R. A variant of the neuronal amino acid transporter SLC6A15 is associated with ACTH and cortisol responses and cognitive performance in unipolar depression. Int. J. Neuropsychopharmacol. 2012, 16:83-90.
127. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., Mirnics K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 2011, 16:751-762.
128. Shioe K., Ichimiya T., Suhara T., Takano A., Sudo Y., Yasuno F., Hirano M., Shinohara M., Kagami M., Okubo Y., Nankai M., Kanba S. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse 2003, 48:184-188.
129. Sibille E., Arango V., Galfalvy H.C., Pavlidis P., Erraji-Benchekroun L., Ellis S.P., Mann J.J. Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacology 2004, 29:351-361.
130. Sibille E., Wang Y., Joeyen-Waldorf J., Gaiteri C., Surget A., Oh S., Belzung C., Tseng G.C., Lewis D.A. A molecular signature of depression in the amygdala. Am. J. Psychiatry 2009, 166:1011-1024.
131. Siegel J.A., Haley G.E., Raber J. Apolipoprotein E isoform-dependent effects on anxiety and cognition in female TR mice. Neurobiol. Aging 2012, 33:345-358.
132. Siffert W. Molecular genetics of G proteins and atherosclerosis risk. Basic Res. Cardiol. 2001, 96:606-611.
133. Smith G.W., Aubry J.-M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.-F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and abberant neuroendocrine development. Neuron 1998, 20:1093-1102.
134. Soliman F., Glatt C.E., Bath K.G., Levita L., Jones R.M., Pattwell S.S., Jing D., Tottenham N., Amso D., Somerville L.H., Voss H.U., Glover G., Ballon D.J., Liston C., Teslovich T., Van Kempen T., Lee F.S., Casey B.J. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 2010, 327:863-866.
135. Sommer W.H., Lidström J., Sun H., Passer D., Eskay R., Parker S.C.J., Witt S.H., Zimmermann U.S., Nieratschker V., Rietschel M., Margulies E.H., Palkovitis M., Laucht M., Heilig M. Human NPY promoter variation rs16147: T>C as a moderator of prefrontal NPY gene expression and negative effect. Human Mut. 2010, 31:E1594-E1608.
136. Soskin D.P., Carl J.R., Alpert J., Fava M. Antidepressant effects on emotional temperament: toward a biobehavioral research paradigm for major depressive disorder. CNS Neurosci. Ther. 2012, 18:441-451.
137. Spijker A.T., van Rossum E.F.C. Glucocorticoid receptor polymorphisms in major depression: focus on glucocortiocoid sensitivity and neurocognitive functioning. Ann. N. Y. Acad. Sci. 2009, 1179:199-215.
138. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berlin) 1985, 85:367-370.
139. Stiedl O., Radulovic J., Lohmann R., Birkenfeld K., Palve M., Kammermeier J., Sananbenesi F., Spiess J. Strain and substrain differences in context- and tone-dependent fear conditioning of inbred mice. Behav. Brain Res. 1999, 104:1-12.
140. Sullivan P.F., Consortium M.D.D.W.G.o.t.P.G. A mega-analysis of genome-wide association studies for major depressive disorder. Mol. Psychiatry 2012, 1:1-15.
141. Sullivan P.F., Neale M.C., Kendler K.S. Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 2000, 157:1552-1562.
142. Sun H.-S., Kennedy P.J., Nestler E.J. Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 2013, 38:124-137.
143. Surget A., Wang Y., Leman S., Ibarguen-Vargas Y., Edgar N., Griebel G., Belzung C., Sibille E. Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 2009, 34:1363-1380.
144. Tasan R.O., Khoi Nguyen N., Weger S., Sartori S.B., Singewald N., Heilbronn R., Herzog H., Sperk G. The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression. J. Neurosci. 2010, 30:6282-6290.
145. Taylor Tavares J.V., Clark L., Furey M.L., Williams G.B., Sahakian B., Drevets W.C. Neural basis of abnormal response to negative feedback in unmedicated mood disorders. Neuroimage 2008, 42:1118-1126.
146. Thoeringer C.K., Henes K., Eder M., Dahlhoff M., Wurst W., Holsboer F., Deussing J.M., Moosmang S., Wotjak C.T. Consolidation of remote fear memories involves cirticotropin-releasing hormone (CRH) receptor type 1-mediated enhancement of AMPA receptor GluR1 signaling in the dentate gyrus. Neuropsychopharmacology 2012, 37:787-796.
147. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 1998, 19:162-166.
148. Touma C., Gassen N.C., Herrmann L., Cheung-Flynn J., Büll D.R., Ionescu I.A., Heinzmann J.-M., Knapman A., Siebertz A., Depping A.-M., Hartmann J., Hausch F., Schmidt M.V., Holsboer F., Ising M., Cox M.B., Schmidt U., Rein T. FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol. Psychiatry 2011, 70:928-936.
149. Tyrka A.R., Price L.H., Gelernter J., Schepker C., Anderson G.M., Carpenter L.L. Interaction of child maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitray-adrenal axis reactivity. Biol. Psychiatry 2009, 66:681-685.
150. Venihaki M., Sakihara S., Subramanian S., Dikkes P., Weninger S.C., Liapakis G., Majzoub J.A. Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J. Neuroendocrinol. 2004, 16:411-422.
151. Weaver I.C.G., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., Dymov S., Szyf M., Meaney M.J. Epigenetic programming by maternal behavior. Nat. Neurosci. 2004, 7:847-854.
152. Wellman C.L., Izquierdo A., Garrett J.E., Martin K.P., Carroll J., Millstein R., Lesch K.-P., Murphy D.L., Holmes A. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J. Neurosci. 2007, 27:684-691.
153. Williams L.M., Gatt J.M., Schofield P.R., Olivieri G., Peduto A., Gordon E. 'Negativity bias' in risk for depression and anxiety: Brain-body fear circuitry correlates, 5-HTT-LPR and early life stress. Neuroimage 2009, 47:804-814.
154. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997, 134:319-329.
155. Wills-Owen S.A., Shifman S., Copley R.R., Flint J. DCNP1: a novel candidate gene for major depression. Mol. Psychiatry 2006, 11:121-122.
156. Xu F., Gainetdinov R.R., Wetsel W.C., Jones S.R., Bohn L.M., Miller G.W., Wang Y.-M., Caron M.G. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat. Neurosci. 2000, 3:465-471.
157. Yamada K., Iida R., Miyamoto Y., Saito K., Sekikawa K., Seishima M., Nabeshima T. Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-a gene: implications for emotional behavior. J. Neuroimmunol. 2000, 111:131-138.
158. Young J.W., Powell S.B., Scott C.N., Zhou X., Geyer M.A. The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav. Brain Res. 2011, 222:183-192.
159. Zhang H.-L., Wu J., Zhu J. The role of apolopoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis. J. Biomed. Biotechnol. 2010, 2010:ID 357412.
160. Zhang T., Chen Y., Liu H., Zhou Z., Zhai Y., Yang J. Chronic unpredictable stress accelerates atherosclerosis through promoting inflammation in apolipoprotein E knockout mice. Thrombosis Res. 2010, 126:386-392.
161. Zimmermann P., Brückl T., Nocon A., Pfister H., Binder E.B., Uhr M., Lieb R., Moffitt T.E., Caspi A., Holsboer F., Ising M. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am. J. Psychiatry 2011, 168:1107-1116.
162. Zörner B., Wolfer D.P., Brandis D., Kretz O., Zacher C., Madani R., Grunwald I., Lipp H.-P., Klein R., Henn F.A., Gass P. Forebrain-specific trkB-receptor knockout mice: behaviourally more hyperactive than depressive. Biol. Psychiatry 2003, 54:972-982.